RNA-based therapies can modulate cells in a controlled and targeted manner, effectively acting as gene therapies. But, as with any therapeutic, RNA therapeutics must undergo strict quality control (QC) to ensure the product is exactly as specified, with no errors or alternate products.
Download this tech note to discover a novel approach that:
- Is ideal for quantitative and qualitative evaluation of primary, full-length RNA products
- Can detect and quantify any intermediates and byproducts
- Is optimal for QC of monovalent and multivalent mRNA-based vaccines or drugs
